Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Why this matters: Three distinct data streams are moving simultaneously on ABBV. Retail attention has jumped to nearly three standard deviations above its 90-day norm. Short sellers have been cutting positions for weeks. Borrow costs whipsawed sharply before collapsing back down. With earnings on October 29, the market is paying closer attention to AbbVie than it has in months.
The most striking reading comes from ORTEX's retail attention measure. Wikipedia views and ORTEX stock page traffic combined hit a z-score of 2.92 against ABBV's own 90-day average as of October 1. That is attention, not a revenue indicator, but a spike that size on a large-cap pharma name is unusual and worth tracking.
The short side has been unwinding in parallel. Short interest fell 10% in a single week, bringing it to 1.02% of free float as of October 1. Over the past month it has dropped 3.7%. The absolute level is low. This is not a stock where short sellers are pressing a thesis.
Borrow costs told a more volatile story over the past two weeks. Cost to borrow spiked 67% to 0.62% on September 25 before collapsing 61% to 0.17% by September 29. It has since settled around 0.34%. The spike looks like a brief, local friction event. It has fully unwound. Borrow availability remains maxed out at the ceiling of the ORTEX scale, with over 1.27 billion shares available to lend against roughly 18 million shorted. There is no tightness anywhere in the lending market.
The options market is marginally more cautious than usual. The put/call ratio sits at 0.87, a z-score of 1.63 above its 20-day mean of 0.82. That is elevated relative to recent history but nowhere near alarming. It sits well below the 52-week high of 1.13.
Analysts have spent the past six weeks raising targets. HSBC lifted its target to $315 in September. Piper Sandler, Wells Fargo, and Guggenheim all raised targets in August. Wolfe Research upgraded the stock to Outperform. The consensus mean target stands at $278.86 against a current price of $259.93, implying roughly 7% upside to the average. HSBC's $315 target implies more than 21%.
The ORTEX short score of 32 has crept up modestly this week, from 31.4 to 32.1, but remains low in absolute terms. The dividend factor score sits at the 98th percentile, and the 12-month forward EPS growth factor scores at the 81st percentile.
On the Medicaid front, ORTEX Alt Data records that Medicaid dollars reimbursed were down 10% year on year in Q1 2026, with prescriptions also down 10% over the same period. None of the alt data datasets for ABBV carry a measured lead status against its financials, so these figures are context rather than a pointer to the upcoming print.
Capital Research and Management added 3.4 million shares in the period to August 31, the largest incremental move among the top institutional holders.
See the live data behind this article on ORTEX.
Open ABBV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
